IFNA2 Protein (AA 24-188)

N° du produit ABIN2666827

Cette protéine Recombinant IFNA2 est produite dans Escherichia coli (E. coli).

Aperçu rapide pour IFNA2 Protein (AA 24-188) (ABIN2666827)

Antigène: IFNA2 (Interferon, alpha 2 (IFNA2))

Type de proteíne: Recombinant

Activité biologique: Active

Origine: Humain

Source: Escherichia coli (E. coli)

Application: Flow Cytometry (FACS), Intracellular Flow Cytometry (ICFC)

Pureté: > 95 % , as determined by Coomassie stained SDS-PAGE.

Détail du produit

Attributs du protein: AA 24-188

Stérilité: 0.22 μm filtered

niveau d'endotoxine:

Less than 0.01 ng per μg cytokine as determined by the LAL method.

Information d'application

Indications d'application: Optimal working dilution should be determined by the investigator.

Commentaires:

Biological activity: Specific activity is 1.86 x 108 units/mg, as determined in a cytopathic effect inhibition assay using EMC virus on A549 cells.

Restrictions: For Research Use only

Stockage

Format: Liquid

Reconstitution: For maximum results, quick spin vial prior to opening. Stock solutions should be prepared at no less than 10 μg/mL in sterile buffer (PBS, HPBS, DPBS, and EBSS) containing carrier protein such as 1 % BSA or HSA. After dilution, the cytokine can be stored between 2 °C and 8 °C for one month or from -20 °C to -70 °C for up to 3 months.

Buffer: 0.22 μm filtered protein solution is in PBS, pH 7.2.

Conseil sur la manipulation: Avoid repeated freeze/thaw cycles.

Stock: -20 °C

Stockage commentaire: Unopened vial can be stored between 2°C and 8°C for three months, at -20°C for six months, or at -70°C for one year.

Détail du antigène

Antigène: IFNA2 (Interferon, alpha 2 (IFNA2))

Autre désignation: IFN-Alpha2

Sujet: Interferons are divided into type I, II, and III. Type I IFNs (IFN-α and IFN-β) are most abundant in number, distribution, and expression. Also, they are highly conserved among mammals in both structure and function. IFN-α2 has been used in the treatment of cancer such as bladder cancer, hepatocellular carcinoma, and leukemia. IFN-α2 augments the suppressed immune functions in patients with head and neck squamous cell carcinoma (HNSCC). IFN-α2 initiated T and NK cell mediated cytotoxicity of tumor cells through IFNγ dependent and independent mechanisms. IFN-α2 enhances suppressed T cell cytotoxicity by stimulation of the perforin-granzyme B system (IFNγ dependent). Also, IFN-α2 induces the expression of perforin-granzyme B in NK cells (NK mediated cytotoxicity, IFNγ independent). In a preliminary study, IFN-α2 appears to be an effective immunostimulator and impacts the clinical outcome in tongue squamous cell carcinoma patients. IFN-α had been used in the treatment of chronic hepatitis C (CHC), nevertheless, IFN-α is relatively unstable and requires frequent parenteral administration. Pegylation of IFN-α, polyethylene glycol (PEG)-IFN-α, reduces in vitro activity but increase the stability and plasma half-life of IFN-α, therefore, PEG-IFN-α has replaced IFN-α in CHC treatment.

Poids moléculaire: The 166 amino acid recombinant protein has a predicted molecular mass of approximately 19.4 kDa. The DTT-reduced and non-reduced proteins migrate at approximately 20 kDa and 18 kDa respectively by SDS-PAGE. The N-terminal amino acid is Met.

Pathways: Signalistation JAK/STAT, Regulation of Leukocyte Mediated Immunity, Production of Molecular Mediator of Immune Response, Hepatitis C